Navigation Links
Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Date:4/30/2008

Adjusted EPS excluding selected items:

EURO 1.43, up 1.4%

$2.14, up 15.7%(1)

PARIS, April 30 /PRNewswire-FirstCall/ -- In order to give a representation of our underlying economic performance, we present and explain an adjusted income statement. We also report adjusted net income and adjusted EPS (excluding selected items) in U.S. dollars(1) in order to facilitate comparisons with the majority of major pharmaceutical groups. Consolidated net income for the first quarter of 2008 was EURO 1,325 million, compared with EURO 1,537 million for the first quarter of 2007.

Operating Results

* Net sales: EURO 6,937 million, up 0.8% on a comparable basis

(-3.3% reported)

* Net sales growth of 7.2%(2) for the Pharmaceuticals business, excluding

the impact of generics of Ambien(R) IR in the United States and

Eloxatin(R) in Europe(3), in line with previous quarters

* Strong growth(2) for Plavix(R) (18.9%), Lovenox(R) (21.5%), Lantus(R)

(30.8%), and Taxotere(R) (13.3%)

* Ongoing cost control and adaptation measures

* Adjusted net income excluding selected items: EURO 1,883 million, or

EURO 1.43 per share

Research & Development

* Positive results from GEMS, the third Phase III trial evaluating

eplivanserin in sleep quality Filing for approval scheduled for the

second half of 2008

* Agreement with Dyax on a human monoclonal antibody and on Phage Display

technology

Confirmation of 2008 Guidance

The first-quarter results support 2008 full-year guidance at constant EURO/dollar parity (1.371), as announced on February 12 (refer to 2008 Guidance section).

2008 first-quarter net sales

Unless otherwise indicated, all sales growth figures in this press release are stated on a comparable basis.

Sanofi-aventis generated first-qua
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... One of the major segments ... for implant dentistry comprises dental implants and abutments ... for dental care is bifurcated into two segments: ... segment is composed of large equipment. , View ... http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html , The worldwide dental market is ...
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its collection of ... player promotion for Dec. 2014. , The CEO of ... April, and this promotion will help to expand our customer ... on our website, she/he can contact us with special need. ... come in the latest designs, and they actually are a ...
(Date:11/27/2014)... Providenciales, Turks and Caicos Islands; BWI (PRWEB) November 28, ... earlier for the Tuscany Resort in the Turks & ... 44 resorts by TripAdvisor in Providenciales, is announcing a ... oceanfront three bedroom villa rentals. And they are ... the resort. , Additionally, The Tuscany, is having ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... Blood-borne pathogens raise the risk of ... procedures in place to counter this. However, it doesn’t ... tainted with menstrual blood are taken as seriously. ... sanitary way to handle tampons and menstrual pads while ... Calif. , He then created a prototype of the ...
Breaking Medicine News(10 mins):Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:The Tuscany on Grace Bay, Top-Rated TripAdvisor Resort in the Turks & Caicos Islands, Offers Special Pre-Christmas & January 2015 Promotions! 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2
... Market for EMR and PACS to Reach $9.3 Billion by ... to a new market research report series by iData Research ... market research firm, the U.S. market for Electronic Medical Records ... to more than quadruple in value by 2013. , An ...
... is one of the most vital and dynamic sectors of ... which needs to keep pace with the evolving demands of ... , , New analysis from Frost & Sullivan ( ... Company Profiles , finds that the global medical device market ...
... ... HEALTHeCAREERS Network , ... Englewood, CO (Vocus) July 7, 2009 -- The Texas Hospital Association (THA) ... the state,s hospital members to hundreds of career Web sites., , , , ,"HEALTHeCAREERS ...
... ... Recent data from the Food and Drug Administration’s Adverse Event Reporting System ... disorders reported by users of Reglan (or its generic version, metoclopramide) more ... the manufacturers of Reglan and metoclopramide to add a black-box ...
... July 7 , - Former England ... Rob Hicks, Call on Men to Bat Away Embarrassment and Take,Appropriate ... innings of the Ashes commencing this week, celebrity TV,presenter and former ... to think about their health as well as the Ashes Test,Series ...
... PROVIDE IMMEDIATE BENEFIT TO HEART , A ... to patients. Researchers from the Feinstein Institute for ... biomarkers associated with cardiovascular disease (CVD) in "at ... showed that smoking cessation resulted in significant reductions ...
Cached Medicine News:Health News:iData Research Publishes Market Analysis Series on Electronic Medical Records and PACS 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 2Health News:Frost & Sullivan Identifies Innovative and Cost-Effective Technology as Key Competitive Factor in European Medical Device Market 3Health News:Texas Hospital Association Endorses HEALTHeCAREERS Network 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 2Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 3Health News:Reglan Adverse Events More Than Doubled from 2006 to 2008 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 2Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 3Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 4Health News:Multimedia Release: British Men Think Talking About Impotence is "Just Not Cricket" 5Health News:News briefs from the July issue of CHEST 2
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: